CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 2.5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456300
NCT00456300Phase 2Completed
CompareCT.gov

The Role of Exenatide in Type 1 Diabetes Mellitus

Montefiore Medical Center·interventional·Posted Apr 4, 2007·Updated Feb 26, 2019

In Brief

A Phase 2 clinical trial evaluating Exenatide and Insulin for Type 1 Diabetes. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of this study is to see if giving exenatide and insulin before a meal would lower blood sugars after the meal. This study may help in developing new treatments to help control high blood sugars after meals. This may help improve overall blood sugar control and prevent the long-term effects of diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.2 years ago

Interventions

Exenatidedrug

In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.

Insulindrug

Each subject received a baseline study with insulin alone